3 ms·

Technically yes, but there are caveats to this. Drug companies regularly create new variants with no distinguishing characteristics but which reset the patent c

Technically yes, but there are caveats to this. Drug companies regularly create new variants with no distinguishing characteristics but which reset the patent clock, using litigation, trademarks, secrets, and other tactics to prevent the original variants being used.

malermeister 3y ago
...which is exactly what the folks at the link are proposing. From their Investment Proposal doc: > However, we can create a new, derivative strain of SMaRT, which would be under new IP protections, and therefore, would very likely be of interest to a large pharma company.